Viagra, the blockbuster erectile dysfunction drug brand of Pfizer that is being introduced in India this week may soon prove to be an equally effective medicine for the treatment of more indications, it is learnt. Clinical trials carried out by the company have shown that Viagra (sidenafil citrate) is very effective in the treatment of pulmonary hypertension. While the global trials confirming the ability of the drug to treat hypertension are nearing completion, trials are also on in India on the new indication.
Pfizer officials who were present at the launch function of Viagra in New Delhi informed that the signals emerging from the trials are very positive. According to Dr Peter Ellis, executive director, Pfizer UK, Viagra is being tested for half a dozen other indications including hypertension. The trials are in various stages and have shown good response in several cases, he informed.
Interestingly, Pfizer is keen on taking up the marketing of its brand in a major way. It expects to have control over 10 to 15% of the ED drug market in another two years. According to Kewal Handa, managing director, Pfzier India, the drug is certainly going to be accepted by a large section of doctors and patients in the country.
“The entry of Viagra, after seven years of sales in major global markets, reflects the change in Pfizer's business plans in India. The company would hereafter attempt to introduce all its new drugs in Indian markets without much time delay,” added Handa.
As Pharmabiz has already reported, Pfizer India has restructured its marketing and sales network into therapeutic business divisions to make maximum use of its efficient field force. The new marketing strategy would also help the company create awareness among the doctors on the benefits of original drugs as against generic versions, informed Pfizer officials.
Pfizer is currently undertaking 34 clinical trials in the country, of which 24 are part of global trials, thereby showing its serious plans for the country.